Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

Blocking the cycle of poly(ADP-ribose) turnover with PARP and PARG inhibitors

J. Zhang

Med Sci Monit 2003; 9(1): 77-0 :: ID: 15220

Abstract

Poly(ADP-ribose) is synthesized from nicotinamide adenine dinucleotide (NAD+) by poly(ADP-ribose) polymerase (PARP) and mainly degraded by poly(ADP-ribose) glycohydrolase (PARG). Overactivation of the poly(ADP-ribose) pathway increases nicotinamide and decreases cellular NAD+/ATP, which leads to cell death. We showed before that PARP inhibitors such as GPI 6150, which was insoluble in water and administered i.p, provided beneficial effects in numerous animal models of diseases. Now we synthesized water-soluble PARP inhibitors, which were not only more potent but also achieved high concentrations in brain, heart and plasma after i.v. administration. We found that iv dosing of the water-soluble PARP inhibitors, e.g. GPI 15427, were efficacious in rodent models of cerebral ischemia, heart ischemia, chemotherapy of tumors, liver transplantation and cardiac arrest. In addition, we investigated whether PARG inhibition could achieve similar protection as an alternative target for the poly(ADP-ribose) cycle. We identified a novel PARG inhibitor, GPI 16552, and demonstrated that either pre- or post-ischemia treatment with the compound significantly reduced brain infarct volumes in a rat model of focal cerebral ischemia. Our result provided the first evidence that PARG inhibitors could ameliorate ischemic brain damage in vivo, in support of PARG as a new therapeutic target for treating ischemia injury.

Keywords: Cell Death, Ischemia, neuroprotection, cardioprotection, chemotherapy

Add Comment 0 Comments

Editorial

01 July 2024 : Editorial  

Editorial: The Global Threats of Increasing Antimicrobial Resistance Require New Approaches to Drug Development, Including Molecular Antimicrobial Adjuvants

Dinah V. Parums

DOI: 10.12659/MSM.945583

Med Sci Monit 2024; 30:e945583

0:00

In Press

Clinical Research  

Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China...

Med Sci Monit In Press; DOI: 10.12659/MSM.944526  

0:00

Clinical Research  

Comparative Analysis of Antihypertensive and Anticonvulsant Regimens in Managing Pre-eclampsia and Eclampsi...

Med Sci Monit In Press; DOI: 10.12659/MSM.944985  

Clinical Research  

Reduced Radial Artery Occlusion in Transradial Cerebral Angiography: Key Predictive Factors and Preventive ...

Med Sci Monit In Press; DOI: 10.12659/MSM.944297  

Database Analysis  

Enhanced Outcomes in Femoral Subtrochanteric Fractures Using Long INTERTAN Nails with Titanium Cable Cercla...

Med Sci Monit In Press; DOI: 10.12659/MSM.944383  

Most Viewed Current Articles

17 Jan 2024 : Review article   4,116,598

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research   1,594,331

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   691,000

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial   50,822

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750